Celebi O, Baser S, Guler M, Taghizadehghalehjoughi A, Rakici E, Aydin E
BMC Microbiol. 2025; 25(1):106.
PMID: 40025436
PMC: 11871791.
DOI: 10.1186/s12866-025-03830-x.
Yuan M, Zong M, Ren C, Zong W, Li Z
Front Oncol. 2024; 14:1444172.
PMID: 39364315
PMC: 11446902.
DOI: 10.3389/fonc.2024.1444172.
Nardulli P, Ballini A, Zamparella M, De Vito D
Microorganisms. 2023; 11(11).
PMID: 38004808
PMC: 10673085.
DOI: 10.3390/microorganisms11112797.
Barbier F, Hraiech S, Kerneis S, Veluppillai N, Pajot O, Poissy J
Ann Intensive Care. 2023; 13(1):65.
PMID: 37462830
PMC: 10354316.
DOI: 10.1186/s13613-023-01153-6.
Ren J, Wang Q, Liu L, Xiao Y, Ji P, Du H
Infect Drug Resist. 2023; 16:1905-1911.
PMID: 37020793
PMC: 10069427.
DOI: 10.2147/IDR.S403527.
Microbiota Assessment of Pediatric Simple and Complex Acute Appendicitis.
Kakar M, Reinis A, Kroica J, Engelis A, Broks R, Asare L
Medicina (Kaunas). 2022; 58(9).
PMID: 36143821
PMC: 9500912.
DOI: 10.3390/medicina58091144.
Intraventricular Plus Systemic Antibiotic Therapy for Treating Polymyxin-Resistant Ventriculitis: A Case Report.
Wang H, Zhou Q, Huang K, Yang X, Wen L
Open Forum Infect Dis. 2022; 9(4):ofac084.
PMID: 35355891
PMC: 8962704.
DOI: 10.1093/ofid/ofac084.
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by and in Critically Ill Adult Patients.
Gatti M, Viaggi B, Rossolini G, Pea F, Viale P
Antibiotics (Basel). 2022; 11(1).
PMID: 35052910
PMC: 8773303.
DOI: 10.3390/antibiotics11010033.
Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by .
Daikos G, da Cunha C, Rossolini G, Stone G, Baillon-Plot N, Tawadrous M
Antibiotics (Basel). 2021; 10(9).
PMID: 34572708
PMC: 8467554.
DOI: 10.3390/antibiotics10091126.
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review.
Soriano A, Carmeli Y, Omrani A, Moore L, Tawadrous M, Irani P
Infect Dis Ther. 2021; 10(4):1989-2034.
PMID: 34379310
PMC: 8355581.
DOI: 10.1007/s40121-021-00507-6.
Successful Treatment of Ventriculitis Caused by MDR/XDR Gram-Negative Bacillus Using Ceftazidime/Avibactam: Case Series and Literature Review.
Zhou Q, Wang H, Zhan T, Yang X, Wen L
Infect Drug Resist. 2021; 14:1691-1701.
PMID: 33981150
PMC: 8107005.
DOI: 10.2147/IDR.S306222.
Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Meningitis.
McCreary E, Byers K, Fernandes C, Kline E, Nicolau D, Shields R
Open Forum Infect Dis. 2021; 7(12):ofaa549.
PMID: 33409327
PMC: 7751399.
DOI: 10.1093/ofid/ofaa549.
Antimicrobial Resistance in ESKAPE Pathogens.
De Oliveira D, Forde B, Kidd T, Harris P, Schembri M, Beatson S
Clin Microbiol Rev. 2020; 33(3).
PMID: 32404435
PMC: 7227449.
DOI: 10.1128/CMR.00181-19.
Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant .
Vena A, Giacobbe D, Castaldo N, Cattelan A, Mussini C, Luzzati R
Antibiotics (Basel). 2020; 9(2).
PMID: 32050434
PMC: 7168189.
DOI: 10.3390/antibiotics9020071.
Inhibition Activity of Avibactam against Nocardia farcinica β-Lactamase FAR.
Lebeaux D, Ourghanlian C, Dorchene D, Soroka D, Edoo Z, Compain F
Antimicrob Agents Chemother. 2019; 64(2).
PMID: 31712200
PMC: 6985717.
DOI: 10.1128/AAC.01551-19.
Multidrug-resistant from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam.
Atkin S, Abid S, Foster M, Bose M, Keller A, Hollaway R
Infect Drug Resist. 2018; 11:1499-1510.
PMID: 30271183
PMC: 6149938.
DOI: 10.2147/IDR.S173804.
Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?.
Nguyen L, Garcia J, Gruenberg K, MacDougall C
Curr Infect Dis Rep. 2018; 20(8):23.
PMID: 29876674
DOI: 10.1007/s11908-018-0629-6.
Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
Sader H, Castanheira M, Shortridge D, Mendes R, Flamm R
Antimicrob Agents Chemother. 2017; 61(11).
PMID: 28827415
PMC: 5655084.
DOI: 10.1128/AAC.01045-17.
Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Wenzler E, Bunnell K, Bleasdale S, Benken S, Danziger L, Rodvold K
Antimicrob Agents Chemother. 2017; 61(7).
PMID: 28416553
PMC: 5487628.
DOI: 10.1128/AAC.00464-17.
